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Abstract
Aims/hypothesis. Studies of the role of sorbitol dehydrogenase in nerve functional deficits induced by diabetes reported contradictory results. We evaluated whether sorbitol dehydrogenase inhibition reduces metabolic abnormalities and enhances oxidative stress characteristic of experimental diabetic neuropathy. Methods. Control and streptozotocin-diabetic rats were treated with or without sorbitol dehydrogenase inhibitor (SDI)-157 (100 mg × kg ±1 × day
±1
, in the drinking water, for 3 weeks). Sciatic nerve free mitochondrial (cristae and matrix) and cytosolic NAD + : NADH ratios were calculated from the b-hydroxybutyrate, glutamate and lactate dehydrogenase systems. Concentrations of metabolites, e. g. sorbitol pathway intermediates and variables of energy state were measured in individual nerves spectrofluorometrically by enzymatic procedures. Results. The flux through sorbitol dehydrogenase (manifested by nerve fructose concentrations) was inhibited by 53 % and 74 % in control and diabetic rats treated with SDI compared with untreated control and diabetic groups. Free NAD + :NADH ratios in mitochondrial cristae, matrix and cytosol were decreased in diabetic rats compared with controls and reduction in either of the three variables was not prevented by sorbitol dehydrogenase inhibitor. Phosphocreatine concentrations and phosphocreatine:creatine ratios were decreased in diabetic rats compared with controls and were further reduced by the inhibitor. Malondialdehyde plus 4-hydroxyalkenals concentration was increased and reduced gluthathione concentration was reduced in diabetic rats compared with the control group, and changes in both variables were further exacerbated by sorbitol dehydrogenase inhibitor. Neither NAD-redox and energy states nor lipid aldehyde and reduced gluthathione concentrations were affected by treatment with the inhibitor in control rats. Conclusion/interpretation. Inhibition of sorbitol dehydrogenase does not offer an effective approach for prevention of oxidation and metabolic imbalances in the peripheral nerve that is induced by diabetes and is adverse rather than beneficial. [Diabetologia (1999) 42: 1187±1194] pletely understood. A number of reports [1, 2, 4 , 10±14] link vascular [4, 15±20] , metabolic [21±24] and neurotrophic [25±27] imbalances that are induced by diabetes to the activity of the first half of the sorbitol pathway, aldose reductase. Some investigators [28, 29] have hypothesized that adverse consequences of increased sorbitol pathway activity in the diabetic nerve are not due to aldose reductase activation itself, but are related to the second half of the sorbitol pathway, sorbitol dehydrogenase (SDH). According to the concept of ªdiabetic pseudohypoxiaº [28] , the increased flux through SDH accounts for NAD-redox imbalances (increase in NADH:NAD + ratio) related to diabetes and constitutes a universal mechanism for development of diabetic complications including neuropathy, retinopathy and nephropathy. Studies of the role for SDH in diabetic complications using SDH inhibitors (SDIs) [4, 30, 31] as well as a SDH-deficient mouse model [32] resulted in contradictory findings. Some groups [29±31] have reported that SDIs reduce nerve conduction deficit induced by diabetes. Others failed to find improved nerve conduction in diabetic rats treated with SDI compared with an untreated diabetic group [4] or in SDH-deficient diabetic mice compared with diabetic mice with normal SDH levels [32] . For a better understanding of biochemical mechanisms underlying diabetic neuropathy, we explored metabolic effects associated with SDH inhibition in diabetic peripheral nerve. Metabolic changes in nerve vasculature, with resulting decrease in nerve blood flow and endoneurial hypoxia, have a key role in nerve conduction slowing in short-term diabetes [4, 15±20] . Metabolic imbalances in the neural tissues, closely associated with impaired neurotrophism [13, 25±27, 33] and neurotransmission [34±36], contribute to Schwann cell injury [37, 38] and axonopathy [39, 40] . These abnormalities which develop gradually and become manifest in long-standing diabetes [38, 39] exacerbate nerve functional deficits acquired in the initial phase of diabetic neuropathy. The importance of sorbitol pathway-linked metabolic imbalances in neural structures is illustrated by findings [41] of a large increase in neuroaxonal dystrophy with SDH inhibition by the dose of SDI not affecting nerve blood flow in the diabetic model of lesser duration [4] . Out of a variety of metabolic variables, we have selected nerve energy status and indices of oxidative stress. Nerve energy status is closely associated with the redox state of free motochondrial and cytosolic NAD-couples, active transport and biosynthetic activity and directly correlates with nerve conduction [42±44] . Oxidative stress has been implicated in the impairment of neurotrophic support and nerve dysfunction in diabetes [26, 45] . We compared our variables in control and diabetic rats treated with or without SDI. We used a prevention approach giving SDI in the drinking water i. e. conditions which, according to some investigators [31] , are essential to show the effects of SDIs. The metabolic effects of SDIs (except those on the sorbitol pathway intermediates [4, 30] ) in the diabetic nerve have only been studied in nonsteady state endoneurial incubations in vitro [29] in high glucose medium. This does not exactly mimic the metabolic environment in diabetic tissues.
Materials and methods
The experiments were done in accordance with regulations specified by The Guiding Principles in the Care and Use of Animals (DHEW Publication, NIH 80±23) and the University of Michigan Protocol for Animal Studies.
Animals. Barrier-sustained, Caesarean-delivered male Wistar rats (Charles River, Wilmington, Mass., USA), body weight 250±300 g, were fed a standard rat chow diet (ICN Biomedicals, Cleveland, Ohio, USA) and had access to water ad libitum. Diabetes was induced by a single intraperitoneal injection of streptozotocin (Upjohn, Kalamazoo, Mich., USA, 55 mg/kg body weight, i. p., in 0.2 ml of 10 mmol/l citrate buffer, pH 5.5) to animals fasted overnight. Blood samples for measurements of glucose were taken from the tail vein about 48 h after the streptozotocin injection and the day before they were killed. The rats with blood glucose of 13.9 mmol/l or more were considered as diabetic. The experimental groups comprised control and 3-week-old diabetic rats treated with or without SDI-157 (Hoechst Marion Roussel, 100 mg × kg body weight ±1 × day ±1 , in the drinking water). The treatment of diabetic rats was started about 48 h after streptozotocin injection.
Reagents. Unless otherwise stated, all chemicals were of reagent-grade quality and were purchased from Sigma Chemical, St. Louis, Mo., USA. Methanol (HPLC grade), perchloric acid, hydrochloric acid, and sodium hydroxide were purchased from Fisher Scientific, Pittsburgh, Pa., USA. Ethyl alcohol (200 proof dehydrated alcohol, U. S. P. punctilious) was purchased from Quantum Chemical Co., Tiscola, Ill., USA. b-d-Glucose, sorbitol, N. F., myo-inositol, C. P., and d-fructose, U. S. P. were purchased from Pfanstiehl Laboratories (Waukegan, Ill., USA). Kits for malondialdehyde and 4-hydroxyalkenals assay were purchased from Oxis International (Portland, Ore., USA).
Experimental procedure. Rats from each group were sedated with carbon dioxide and subsequently killed by cervical dislocation. The femoral segments of the left sciatic nerve from each rat were rapidly (~30 s) dissected, carefully blotted with fine filter paper to remove any accompanying blood and frozen in liquid nitrogen for subsequent measurements of b-hydroxybutyrate, acetoacetate, glutamate, a-ketoglutarate, ammonia, phosphocreatine, creatine and ATP. The remaining part of the left nerve and the right nerve were used for measurements of total malondialdehyde plus 4-hydroxyalkenals, reduced glutathione and sorbitol pathway intermediates.
It has been suggested (D. R. Tomlinson, personal communication) that euthanasia with prior sedation by carbon dioxide can cause respiratory acidosis and thus lead to a distorted nerve metabolite profile. This point was examined in a pilot experiment in which non-diabetic rats were killed either by decapitation without any anaesthesia (n = 10) or by cervical dislocation after prior sedation with CO 2 (n = 8). The rats were exposed to carbon dioxide (~15±20 s) in a specially designed plastic chamber with two compartments. The lower compartment contained dry ice (the source of CO 2 ) and was separated from the upper compartment (used as a rat container) by a septum perforated with numerous small holes. There was no difference found in the sciatic nerve reduced metabolite and high-energy phosphate concentrations between CO 2 -sedated and decapitated groups. Concentrations (in mmol/g wet weight) of lactate were 1.49 ± 0.39 and 1.86 ± 0.43, pyruvate: 0.167 ± 0.018 and 0.142 ± 0.024, malate: 0.118 ± 0.030 and 0.131 ± 0.043, phosphocreatine: 2.86 ± 0.36 and 2.45 ± 0.44, and ATP: 0.902 ± 0.227 and 0.840 ± 0.272, respectively. No difference was found in free cytosolic NAD + :NADH ratios (1054 ± 202 and 871 ± 235), calculated as below. A tendency towards an increase in reduced metabolite concentrations and decrease in phosphocreatine and ATP concentrations and free cytosolic NAD + :NADH ratio in the decapitated compared with the CO 2 -sedated group can be explained by difficulties in dissecting sciatic nerves immediately after decapitation because of seizures of the body. The sampling time, critical for metabolites of dehydrogenase reactions as well as high-energy phosphates, was about 20 s longer for the decapitated than for the CO 2 -sedated group.
Measurements of sorbitol pathway intermediates and total malondialdehyde plus 4-hydroxyalkenals. Nerve segments (~40 mg) were weighed and homogenized in 1 ml 0.1 mol/l sodium-phosphate buffer, pH 6.5. A volume of 0.1 ml of 0.3 mol/l zinc sulphate, followed by an equivalent of barium hydroxide, was then added to 0.4 ml of the homogenate for protein precipitation. The samples were centrifuged at 4000´g for 10 min (Sorvall MC 12V, Newton, Conn., USA) and aliquots of the supernatant were taken for spectrofluorometric measurements of glucose, sorbitol and fructose by enzymatic procedures as described previously [46, 47] . The rest of the homogenate was centifuged at 3000´g for 5 min. Then 0.2 ml of supernatant was used for measurements of total malondialdehyde plus 4-hydroxyalkenals using LPO-586 kits from Oxis International (Portland, Ore., USA). The method [48] is based on the reaction of a chromogenic reagent, N-methyl-2-phenylindole with malondialdehyde and 4-hydroxyalkenals, after their extraction under methanesulphonic acidic conditions, at 45°C. The absorbance of chromogenic product was measured at 586 nm using a spectrophotometer Beckman DU 640 (Fullerton, Calif., USA) and was compared with the absorbance in corresponding standards.
Preparation of perchloric extract. Femoral segments (~20 mg) of the left nerve as well as segments (~20 mg) of a remaining part of the left nerve or the right nerve were weighed, homogenized in 1.5 ml of ice-cold 6 % HCIO 4 and centrifuged at 4000´g for 10 min. After centrifugation the samples were immediately neutralized with 5 mol/l K 2 CO 3 to pH 6±7 and were centrifuged again at 4000´g for 5 min to precipitate insoluble KClO 4 .
Measurements of glycolytic and tricarboxylic acid cycle intermediates, ketone bodies, glutamate, ammonia, high-energy phosphates and creatine. The steady-state concentrations of acetoacetate, b-hydroxybutyrate, glutamate, a-ketoglutarate, ammonia, lactate, pyruvate, phosphocreatine, creatine and ATP were assayed in perchloric extracts of femoral segments of the left sciatic nerve spectrofluorometrically (Perkin-Elmer LS-5B, Norwalk, Conn., USA) by enzymatic procedures as described [49] . The lower limit for all spectrofluorometric procedures in our study including glucose, sorbitol and fructose was 0.1´10 ±9 mol/l.
GSH measurements. We modified a reported method [50] and mixed 0.1 ml of neuralized nerve perchloric extracts with 0.89 ml of 20 mmol/l EDTA in 1.0 mol/l TRIS-HCl buffer (pH 8.1). The reaction was initiated by addition of 0.01 ml of 0-phthaldialdehyde (10 mg±1 ml methanol). Initial and final readings were taken at l excitation: 345 nm, l emission: 425 nm, slits: 5 and 5. The differences in initial and final readings were compared with those in corresponding GSH standards (1±10´10 ±9 M) processed in the same run.
Calculations of free mitochondrial and cytosolic NAD + :NADH ratios. According to classical publications of Krebs' laboratory [51, 52] and other studies [53] , direct measurements of NAD, NADH, NADP and NADPH do not provide information on compartmentalization of nicotinamide adenine nucleotides between cytosol and mitochondria and do not separate free from protein-bound forms (only free forms determine direction and free-energy changes of dehydrogenase reactions). The same studies proposed an alternative approach for assessment of free NAD(P) + :NAD(P)H ratios in the cytoplasm and mitochondria from ratios of the concentrations of oxidized and reduced metabolites of suitable NAD(P)-linked dehydrogenase systems. Using this approach, free NAD + :NADH ratios for mitochondrial cristae, matrix as well as cytoplasm were calculated from the steady-state metabolite concentrations and the equilibrium constants of b-hydroxybutyrate, glutamate and lactate dehydrogenase systems as described [51, 53] 
Results
Although the initial body weights were similar the final body weights were lower in diabetic rats than in control rats (Table 1) . No significant difference was found between body weights in control and diabetic rats treated with SDI and the corresponding untreated groups. Blood glucose concentrations were increased about 4.8-fold in diabetic rats compared with those in control rats. Treatment with SDI had no effect on blood glucose concentrations in either control or diabetic rats.
Sciatic nerve glucose concentrations were 3.6-fold higher in diabetic rats compared with those in control rats ( Table 2 ). Treatment with SDI had no effect on nerve glucose concentrations in either control or diabetic rats. Sorbitol concentration was increased 10.9-fold and fructose concentration reduced 2.1-fold in control rats treated with SDI compared with the untreated group. Concentrations of sorbitol and fructose were increased 11.1-fold and 5.5-fold by diabetes. Treatment with SDI caused a 4.4-fold increase in nerve sorbitol and 3.8-fold reduction in nerve fructose in diabetic rats.
Concentrations of acetoacetate, b-hydroxybutyrate, glutamate, a-ketoglutarate, ammonia, lactate and pyruvate were similar in the sciatic nerves of control rats treated with and without SDI ( Table 3) . Concentrations of acetoacetate and b-hydroxybutyrate were increased 4.5-fold and sevenfold in diabetic rats compared with those in control rats and these variables were not affected by SDI teatment. Concentrations of glutamate and ammonia were increased 1.5-fold and 1.3-fold by diabetes and an increase of both variables was completely prevented by SDI treatment. Concentrations of a-ketoglutarate tended to decrease in diabetes although the difference to the control group did not achieve statistical significance and were reduced in diabetic rats treated with SDI (1.7-fold vs control group). Lactate concentrations were increased 2.8-fold in diabetic rats compared with those in control rats and this increase was reduced by SDI treatment. No significant difference was found between pyruvate concentrations in control and untreated diabetic rats whereas pyruvate concentrations in diabetic rats treated with SDI appeared to be reduced compared with those in the untreated diabetic group (p = 0.05).
Free NAD + :NADH ratios in nerve mitochondrial cristae (Fig. 1,A) , matrix (Fig. 1,B) and cytosol ( Fig. 1,C) were decreased 1.8-fold, 1.5-fold and twofold in diabetic rats compared with those in control rats. None of these variables was affected by SDI treatment in either control or diabetic rats.
Nerve ATP concentrations were similar in control and diabetic groups treated with and without SDI ( Table 4) . Phosphocreatine concentrations and phosphocreatine:creatine ratios were not different in control rats treated with and without SDI. Both phosphocreatine concentrations and phosphocreatine:creatine ratios were reduced in diabetic rats (1.3-fold and 1.7-fold vs control group) and the decrease in both variables was further exacerbated by SDI treatment (1.6-fold and 1.4-fold vs untreated diabetic group and 2.1-fold and 2.3-fold vs control group). Creatine concentrations were not different among control and diabetic rats treated with and without SDI. Nerve total malondialdehyde plus 4-hydroxyalkenals ( Fig. 2A) and GSH concentrations (Fig. 2,B) were similar in control rats treated with and without SDI. Total malondialdehyde plus 4-hydroxyalkenals concentrations were increased whereas GSH concentrations were reduced in diabetic rats compared with control rats (p < 0.01 for both comparisons). The increase in total malondialdehyde plus 4-hydroxyalkenals and the reduction in GSH were further exacerbated by SDI treatment (p < 0.05 and p < 0.01 vs untreated diabetic group, respectively).
Discussion
Our study shows that diabetes causes a considerable reduction in the free NAD + :NADH ratio, i. e. a shift towards a more reduced state of free mitochondrial NAD-couple, in the nerve mitochondrial cristae which can be regarded as metabolic evidence of endoneurial hypoxia. This is consistent with findings of decreased blood flow in both exposed [4, 54±58] and unexposed [59] diabetic nerve. The shifts in free NAD + :NADH ratios in mitochondrial matrix and cristae appear unidirectional. This is predictable considering the dependence of NADH-generating capacity of the tricarboxylic acid cycle, localized in mitochondrial matrix, on the efficacy of NADH oxidation by the respiratory chain in mitochondrial cristae [60] . The absence of any improvement in free NAD + :NADH ratios in nerve mitochondrial matrix and cristae in the diabetic rats treated with SDI compared with the untreated diabetic group is consistent with a previous report of the lack of any effect of this compound on nerve blood flow [4] .
In spite of the effective inhibition of SDH in the diabetic peripheral nerve with the applied dose of SDI (consistent with the study [30] ) we did not observe any increase in free cytosolic NAD + :NADH ratio. This does not agree with the report [29] of decreased NAD-redox imbalances (expressed as lactate:pyruvate ratios) in incubated endoneurial preparations from diabetic rats treated with SDI. Our results differ from those [29] despite the the use of similar (prevention) design, similar duration of diabetes and a more profound inhibition of SDH in our experiments. Our findings do not support the key role of SDH in cytosolic NAD-redox imbalances in the diabetic nerve. The decrease induced by diabetes in the nerve-free cytosolic NAD + :NADH ratio is probably of mitochondrial origin, because cytoplasmic and mitochondrial pools of nicotinamide nucleotides are linked through dicarboxylate carriers and the nerve strongly depends on aerobic metabolism [42, 61] .
The changes in high-energy phosphates induced by diabetes in our study are consistent with previous reports [42, 43] . Note that SDI treatment exacerbated both phosphocreatine deficit and decrease in the phosphocreatine/creatine ratio, the most sensitive variable of neural tissue energy status [62, 63] in the diabetic peripheral nerve. Although this phenomenon requires specific studies, at least two putitative underlying mechanisms can be invoked. Excessive sorbitol accumulation in the peripheral nerve of rats treated with SDI can potentially cause (through Ca ++ or another mediator) uncoupling of mitochondrial oxidation and phosphorylation and thus lead to a depletion of phosphocreatine, the storage form of highenergy phosphates. That an osmotic factor is involved is supported by decreased phosphocreatine concentrations in the peripheral nerve of rats after 10 days of feeding with 50 % galactose but not in rats which have been diabetic for 10 days (nerve galactitol accumulation in the galactose-fed rats exceeded~13-fold nerve sorbitol accumulation in the diabetic group) (I. Obrosova, unpublished observations). It is also supported by experiments with DL-a-lipoic acid which increased nerve sorbitol accumulation [44, 64] and did not prevent decrease in either phosphocreatine concentrations [64] or the phosphocreatine:creatine ratio [44] , in spite of the preservation of normal blood flow [16, 44] and free mitochondrial NAD: NADH ratios [44] , in the ªyoungº [65] streptozotocin model of diabetes. Another explanation for exacerbation of energy deficiency induced in diabetes by SDI is the possibility that the sorbitol pathway is the route providing fructose-6-phosphate for anaerobic glycolysis [66] , bypassing hexokinase. Aerobic metabolism of the diabetic peripheral nerve is depressed due to hypoxia and activated glycolysis represents an important compensatory mechanism of high-energy phosphate production [42, 61] . Hexokinase has a high affinity for glucose [67] and is easily saturated [68] thus becoming the rate-limiting step for the glycolytic flux. The peripheral nerve can use fructose as an alternative source of energy [69] and the presence of fructose-1-phosphate, which can be formed from fructose and isomerized to fructose-6-phosphate, in the nerve has been documented [70] . Thus, the inhibition of SDH in diabetes eliminates the potentially important source of glycolytic intermediates which, due to inhibition of glycolysis, would ultimately result in energy failure. Although the provision of fructose-6-phosphate by the sorbitol pathway would also be blocked by aldose reductase inhibitors, the latter is unimportant for the diabetic nerve energy status as aldose reductase inhibition ameliorates nerve blood flow [4, 71] and eliminates endoneurial hypoxia [71] thus improving aerobic glucose oxidation providing much greater energy yield than the anaerobic glycolysis [72] .
Nerve GSH concentration obtained with O-phthaldialdehyde assay in our experiments is in agreement with studies which have used HPLC [16] and the colorimetric procedure with Ellman's reagent [73] . Decrease of nerve GSH concentration induced by diabetes is consistent with a previous report [16] and parallels accumulation of malondialdehyde plus 4-hydroxyalkenals, the products of lipid peroxidation. Exacerbation of both lipid aldehyde accumulation and GSH depletion induced by diabetes by SDI treatment as well as the lack of any prooxidant properties of the SDI-157 in itself (manifested by the absence of lipid aldehyde accumulation and GSH depletion in non-diabetic rats treated with SDI compared with an untreated group), indicates that SDI treatment enhances indirectly oxidative stress induced by diabetes.
In conclusion, our findings do not support the concept of ªdiabetic pseudohypoxiaº, and imply that minor flux through SDH can not account for the changes in such a dynamic system as the redox state of nicotinamide dinucleotides, in the diabetic nerve. Our results are consistent with observations of other groups showing that SDH inhibition does not offer an effective approach for treatment of functional [4] and metabolic [12] deficits characteristic for experimental diabetic neuropathy. Moreover, exacerbation of energy deficiency and oxidative stress induced by SDI indicates that SDH inhibition in the peripheral nerve in diabetes is adverse rather than beneficial and is in agreement with the findings of a large increase in neuroaxonal dystrophy [41] rather than with reports of beneficial effects of SDIs.
